EPAS1 and neoplasm: reported that 4 of 92 pediatric patients (4.3%) compared to 5 of 519 adult patients (1.0%) with PPGL were found to have a somatic mutation in EPAS1 from tumor tissue, emphasizing how frequently cluster 1 mutations, even post-zygotic mutations, are seen in the pediatric population (2).